Review




Structured Review

Regulus Therapeutics rg-101
Rg 101, supplied by Regulus Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rg-101/rg+101/pm40562220-154-6-3
Average 90 stars, based on 1 article reviews
rg-101 - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Sequencing:

Article Title: Antisense oligonucleotides as drugs with both direct and indirect antiviral actions.
Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Article Title: Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications.
Article Snippet: For example, RG-101, developed by Regulus Therapeutics, is an GalNAc-conjugated anti-miRNA oligonucleotide sequence to target miRNA-122 against hepatitis C virus infection [40].

Article Title: Trials and Tribulations of MicroRNA Therapeutics
Article Snippet: RG-101: RG-101, an antagomir of miR-122 developed by Regulus Therapeutics, is an N-acetyl-d-galactosamine(GalNAc)-conjugated synthetic RNA oligonucleotide that targets and inhibits miR-122, which is involved in HCV replication for patients with HCV.

Article Title: RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges
Article Snippet: RG-101 , miR-122 , chronic hepatitis C , Regulus Therapeutics , Discontinued.

Article Title: The MSC-EV-microRNAome: A Perspective on Therapeutic Mechanisms of Action in Sepsis and ARDS.
Article Snippet: Miravirsen (produced by Roche/Santaris) and RG-101 (produced by Regulus Therapeutics), designed to treat hepatitis C, are considered the flagship products of this class of future drugs [51–56].

Article Title: Host-Targeting Antivirals for Chronic Viral Infections of the Liver.
Article Snippet: For RG-101, reports about serious adverse effects, including jaundice and liver 523 toxicity, forced the FDA to place a clinical hold in 2016 (Investors - Regulus Therapeutics, 524 2024).

Article Title: Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies.
Article Snippet: INT-1B3 has its foundation in miR-193a-3p, a miRNA that, when downregulated, is linked to cancer, metastasis, and therapeutic resistance.35 Additionally, Regulus Therapeutics and SantarisPharma are respectively developing, Rg-101 and Miravirsen, two antiviral treatments for the Hepatitis C virus (HCV).

Article Title: Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications
Article Snippet: For example, RG-101, developed by Regulus Therapeutics, is an GalNAc-conjugated anti-miRNA oligonucleotide sequence to target miRNA-122 against hepatitis C virus infection [ ].

Virus:

Article Title: Antisense oligonucleotides as drugs with both direct and indirect antiviral actions.
Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Article Title: Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications.
Article Snippet: For example, RG-101, developed by Regulus Therapeutics, is an GalNAc-conjugated anti-miRNA oligonucleotide sequence to target miRNA-122 against hepatitis C virus infection [40].

Article Title: Trials and Tribulations of MicroRNA Therapeutics
Article Snippet: RG-101: RG-101, an antagomir of miR-122 developed by Regulus Therapeutics, is an N-acetyl-d-galactosamine(GalNAc)-conjugated synthetic RNA oligonucleotide that targets and inhibits miR-122, which is involved in HCV replication for patients with HCV.

Article Title: RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges
Article Snippet: RG-101 , miR-122 , chronic hepatitis C , Regulus Therapeutics , Discontinued.

Article Title: The MSC-EV-microRNAome: A Perspective on Therapeutic Mechanisms of Action in Sepsis and ARDS.
Article Snippet: Miravirsen (produced by Roche/Santaris) and RG-101 (produced by Regulus Therapeutics), designed to treat hepatitis C, are considered the flagship products of this class of future drugs [51–56].

Article Title: Host-Targeting Antivirals for Chronic Viral Infections of the Liver.
Article Snippet: For RG-101, reports about serious adverse effects, including jaundice and liver 523 toxicity, forced the FDA to place a clinical hold in 2016 (Investors - Regulus Therapeutics, 524 2024).

Article Title: Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies.
Article Snippet: INT-1B3 has its foundation in miR-193a-3p, a miRNA that, when downregulated, is linked to cancer, metastasis, and therapeutic resistance.35 Additionally, Regulus Therapeutics and SantarisPharma are respectively developing, Rg-101 and Miravirsen, two antiviral treatments for the Hepatitis C virus (HCV).

Article Title: Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications
Article Snippet: For example, RG-101, developed by Regulus Therapeutics, is an GalNAc-conjugated anti-miRNA oligonucleotide sequence to target miRNA-122 against hepatitis C virus infection [ ].

Infection:

Article Title: Antisense oligonucleotides as drugs with both direct and indirect antiviral actions.
Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Article Title: Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications.
Article Snippet: For example, RG-101, developed by Regulus Therapeutics, is an GalNAc-conjugated anti-miRNA oligonucleotide sequence to target miRNA-122 against hepatitis C virus infection [40].

Article Title: Trials and Tribulations of MicroRNA Therapeutics
Article Snippet: RG-101: RG-101, an antagomir of miR-122 developed by Regulus Therapeutics, is an N-acetyl-d-galactosamine(GalNAc)-conjugated synthetic RNA oligonucleotide that targets and inhibits miR-122, which is involved in HCV replication for patients with HCV.

Article Title: RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges
Article Snippet: RG-101 , miR-122 , chronic hepatitis C , Regulus Therapeutics , Discontinued.

Article Title: The MSC-EV-microRNAome: A Perspective on Therapeutic Mechanisms of Action in Sepsis and ARDS.
Article Snippet: Miravirsen (produced by Roche/Santaris) and RG-101 (produced by Regulus Therapeutics), designed to treat hepatitis C, are considered the flagship products of this class of future drugs [51–56].

Article Title: Host-Targeting Antivirals for Chronic Viral Infections of the Liver.
Article Snippet: For RG-101, reports about serious adverse effects, including jaundice and liver 523 toxicity, forced the FDA to place a clinical hold in 2016 (Investors - Regulus Therapeutics, 524 2024).

Article Title: Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies.
Article Snippet: INT-1B3 has its foundation in miR-193a-3p, a miRNA that, when downregulated, is linked to cancer, metastasis, and therapeutic resistance.35 Additionally, Regulus Therapeutics and SantarisPharma are respectively developing, Rg-101 and Miravirsen, two antiviral treatments for the Hepatitis C virus (HCV).

Article Title: Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications
Article Snippet: For example, RG-101, developed by Regulus Therapeutics, is an GalNAc-conjugated anti-miRNA oligonucleotide sequence to target miRNA-122 against hepatitis C virus infection [ ].



Similar Products

90
Regulus Therapeutics rg-101
Rg 101, supplied by Regulus Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rg-101/rg+101/pm40562220-154-6-3
Average 90 stars, based on 1 article reviews
rg-101 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Janssen rg-101
Rg 101, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rg-101/rg+101/pm39716667-267-13-14
Average 90 stars, based on 1 article reviews
rg-101 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Regulus Therapeutics mir-122-5p inhibitor rg-101
Mir 122 5p Inhibitor Rg 101, supplied by Regulus Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rg-101/rg+101/pmc11011542-70-0-30
Average 90 stars, based on 1 article reviews
mir-122-5p inhibitor rg-101 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Regulus Therapeutics rg-101 (for viral effect targeting mir-122)
Rg 101 (For Viral Effect Targeting Mir 122), supplied by Regulus Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rg-101/rg+101/pmc10385075-92-46-61
Average 90 stars, based on 1 article reviews
rg-101 (for viral effect targeting mir-122) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results